Loading…
← CockpitCompetitor Analysis › 219A.T Heartseed, Inc.Open in the cockpit ↗

Heartseed, Inc.219A.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum leader 98
Mkt cap
$392M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$9.66M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+30.4 pp
WACC 6.1%
Hurdle
-27 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · JPY¥2,733
1D-4.2%
1W-9.7%
1M+4.9%
3M+40.9%
6M+53.3%
YTD+51.5%
1Y+56.8%
ATR %6.9%
52w lowhigh14.9% off high

What Heartseed does

Employees: 43

Heartseed at a glance

Size Heartseed (219A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $392M, the 1191st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,733 on 18 Nov 2026.

Performance Over six months the shares gained 53.3%, against -18.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 196.9% over the last twelve months (peer median -13.1%); the operating margin is 9.0% (peer median -18.2%).

Valuation It trades at 21.9× enterprise value to sales against a peer median of 4.4× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +73%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 30.4 points above its cost of capital (6.1% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026219A.T 170Peer median 82
Six months, rebased to 100: Heartseed against the median of its 20 peers (local-currency closes).

Heartseed financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a¥2.59B¥874M¥345M¥499M
Revenue growth—+197%+153%-31%—
EBITDAn/a¥279M-¥997M-¥1.45B-¥1.46B
Net incomen/a¥163M-¥813M-¥1.47B-¥1.41B
Free cash flown/a¥1.05B-¥1.36B-¥1.13B-¥1.92B
Capital expendituren/a¥28.7M¥14.0M¥328M¥0
Total debt¥500M¥252,000¥5.39M¥11.6M¥31.0M

Quarterly statements and history in the cockpit →

Heartseed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%300452AVTX42C30053430063645920028680025814552IRD6535002864CTMX688399RZLT7871PBYI219A.T6-month return →1-month return →
Up and to the right = strong over both horizons. Heartseed is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×200×400×30045242CSHUKRAPHAR30053465357871219A.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Heartseed is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%300452300534300636000931002864PBYI219A.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Heartseed is the large dot.

Heartseed competitors and peer comparison

How Heartseed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Heartseed against its 20 peers (data as of 18 Nov 2026)
Measure219A.TPeer medianRank in peer set
1-month return+4.9%-12.9%4th highest of 21
6-month return+53.3%-18.5%2nd highest of 20
Distance from 52-week high-14.9%-47.4%2nd highest of 21
Revenue growth (TTM)+196.9%-13.1%3rd highest of 19
Operating margin9.0%-18.2%4th highest of 19
EV / Sales21.9×4.4×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)46.5%4.7%most demanding of 7
Growth delivered (Del g)+73.2%+11.7%highest of 7
Hurdle (Req g minus delivered)-26.7 pp-3.7 ppleast demanding of 7
ROIC minus cost of capital+30.4 pp-3.6 pp2nd highest of 16
Net debt / EBITDA-20.6×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a

Questions

Which companies are Heartseed's closest peers?
The cockpit's peer set: Anhui Sunhere Pharmaceutical Excipients (300452.SZ), Avalo Therapeutics (AVTX), iX Biopharma (42C.SI), Shukra Pharmaceuticals (SHUKRAPHAR.NS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Jiangxi Synergy Pharmaceutical (300636.SZ), SanBio (4592.T), Lifecome Biochemistry (002868.SZ).
Is Heartseed expensive compared with its peers?
On ev / sales it trades at 21.9× against a peer median of 4.4×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +73%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has Heartseed stock performed?
Over six months to 18 Nov 2026 the shares returned +53.3% against -18.5% for the median peer; over one year +56.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.